Gnubiotics Sciences raises CHF 2.6 million in Series A1 financing round
30.07.2020
Gnubiotics Sciences SA, a Swiss biotech dedicated to revolutionizing microbiome health in humans and animals, has secured CHF 2.6 million in a Series A1, which included current shareholders and new investors.
 Gnubiotics team
|
 |
In parallel, Lausanne-based Gnubiotics has also secured a CHF 787,000 loan from UBS, backed by the Canton de Vaud and Swiss Confederation. With this new round of funding and loan, Gnubiotics’ total funds raised add up to CHF 9.5 million.
The new funds will accelerate the commercialization activities of Gnubiotics’ first pipeline candidate, AMObiome. AMObiome is an animal milk oligosaccharide biosimilar to be used as nutritional support for microbiome diversity and crucial for the life-long gut health of animals.
Gnubiotics was a Venture Kick winner in 2017 and one of the TOP 100 Swiss startups in 2017 and 2018.
The new funds will accelerate the commercialization activities of Gnubiotics’ first pipeline candidate, AMObiome. AMObiome is an animal milk oligosaccharide biosimilar to be used as nutritional support for microbiome diversity and crucial for the life-long gut health of animals.
Gnubiotics was a Venture Kick winner in 2017 and one of the TOP 100 Swiss startups in 2017 and 2018.